LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company specializing in the development of treatments for ocular conditions and currently valued at $37 million, has ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal ...

Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The ...

Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Researchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.

Researchers at Leipzig University’s Faculty of Medicine and Shandong University in China have discovered a new mechanism that ...

Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.